What is WuXi PharmaTech (Cayman) Cyclically Adjusted FCF per Share?
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
WuXi PharmaTech (Cayman)'s adjusted free cash flow per share for the three months ended in Sep. 2015 was $0.000. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Sep. 2015.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.
As of today (2024-05-05), WuXi PharmaTech (Cayman)'s current stock price is $45.90. WuXi PharmaTech (Cayman)'s Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2015 was $0.00. WuXi PharmaTech (Cayman)'s Cyclically Adjusted Price-to-FCF of today is .
WuXi PharmaTech (Cayman) Cyclically Adjusted FCF per Share Historical Data
The historical data trend for WuXi PharmaTech (Cayman)'s Cyclically Adjusted FCF per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi PharmaTech (Cayman) Cyclically Adjusted FCF per Share Chart
|
WuXi PharmaTech (Cayman) Annual Data
|
|
Trend |
Dec05 |
Dec06 |
Dec07 |
Dec08 |
Dec09 |
Dec10 |
Dec11 |
Dec12 |
Dec13 |
Dec14 |
| Cyclically Adjusted FCF per Share |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
WuXi PharmaTech (Cayman) Quarterly Data
|
|
Dec10 |
Mar11 |
Jun11 |
Sep11 |
Dec11 |
Mar12 |
Jun12 |
Sep12 |
Dec12 |
Mar13 |
Jun13 |
Sep13 |
Dec13 |
Mar14 |
Jun14 |
Sep14 |
Dec14 |
Mar15 |
Jun15 |
Sep15 |
| Cyclically Adjusted FCF per Share |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of WuXi PharmaTech (Cayman)'s Cyclically Adjusted FCF per Share
For the Diagnostics & Research subindustry, WuXi PharmaTech (Cayman)'s Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi PharmaTech (Cayman)'s Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi PharmaTech (Cayman)'s Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where WuXi PharmaTech (Cayman)'s Cyclically Adjusted Price-to-FCF falls into.
WuXi PharmaTech (Cayman) Cyclically Adjusted FCF per Share Calculation
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?
Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.
We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, WuXi PharmaTech (Cayman)'s adjusted Free Cash Flow per Share data for the three months ended in Sep. 2015 was:
| Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Sep. 2015 (Change) | * | Current CPI (Sep. 2015) |
| = | 0 | / | 100.5000 | * | 100.5000 |
| = | 0.000 |
Current CPI (Sep. 2015) = 100.5000.
WuXi PharmaTech (Cayman) Quarterly Data
|
Free Cash Flow per Share |
CPI |
Adj_FreeCashFlowPerShare |
| 200512 |
0.000 |
75.666 |
0.000 |
| 200603 |
0.000 |
76.340 |
0.000 |
| 200606 |
0.000 |
76.034 |
0.000 |
| 200609 |
0.000 |
76.413 |
0.000 |
| 200612 |
0.000 |
77.793 |
0.000 |
| 200703 |
0.281 |
78.884 |
0.358 |
| 200706 |
-0.527 |
79.357 |
-0.667 |
| 200709 |
0.000 |
81.276 |
0.000 |
| 200712 |
0.452 |
82.911 |
0.548 |
| 200803 |
0.000 |
85.485 |
0.000 |
| 200806 |
-0.894 |
85.058 |
-1.056 |
| 200809 |
0.000 |
85.057 |
0.000 |
| 200812 |
0.000 |
83.956 |
0.000 |
| 200903 |
0.000 |
84.457 |
0.000 |
| 200906 |
0.000 |
83.615 |
0.000 |
| 200909 |
0.000 |
84.369 |
0.000 |
| 200912 |
0.000 |
85.386 |
0.000 |
| 201003 |
0.000 |
86.316 |
0.000 |
| 201006 |
0.000 |
85.886 |
0.000 |
| 201009 |
0.000 |
87.267 |
0.000 |
| 201012 |
0.000 |
89.289 |
0.000 |
| 201103 |
0.000 |
91.154 |
0.000 |
| 201106 |
0.000 |
91.612 |
0.000 |
| 201109 |
0.000 |
92.711 |
0.000 |
| 201112 |
0.000 |
92.885 |
0.000 |
| 201203 |
0.000 |
94.367 |
0.000 |
| 201206 |
0.000 |
93.495 |
0.000 |
| 201209 |
0.000 |
94.482 |
0.000 |
| 201212 |
0.000 |
95.237 |
0.000 |
| 201303 |
0.000 |
96.372 |
0.000 |
| 201306 |
0.000 |
95.984 |
0.000 |
| 201309 |
0.000 |
97.332 |
0.000 |
| 201312 |
0.000 |
97.624 |
0.000 |
| 201403 |
0.000 |
98.600 |
0.000 |
| 201406 |
0.000 |
98.200 |
0.000 |
| 201409 |
0.000 |
98.900 |
0.000 |
| 201412 |
0.000 |
99.000 |
0.000 |
| 201503 |
0.000 |
99.900 |
0.000 |
| 201506 |
0.000 |
99.500 |
0.000 |
| 201509 |
0.000 |
100.500 |
0.000 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
WuXi PharmaTech (Cayman) (WuXi PharmaTech (Cayman)) Business Description
Traded in Other Exchanges
N/A
Address
WuXi PharmaTech (Cayman) Inc was incorporated on March 16, 2007 and commenced operations and began offering pharmaceutical and biotechnology R&D outsourcing services in 2001. The Company is a pharmaceutical, biotechnology and medical device R&D services company, with operations in China and the United States. It provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers, which includes pharmaceutical, biotechnology and medical device companies. Its services are designed to assist its customers in shortening the cycle and lowering the cost of pharmaceutical and medical device R&D by providing cost-effective and efficient outsourcing solutions. Its primary China-based facilities include 1,127,000 square feet of facilities in the China (Shanghai) Pilot Free Trade Zone used for synthetic chemistry, biology, medicinal chemistry, DMPK, formulation, analytical development, manufacturing process chemistry, research manufacturing, bioanalytical services, genomics, and biologics drug discovery and development; an R&D center in Tianjin engaged in synthetic chemistry and medicinal chemistry; a facility in Wuhan providing services in synthetic chemistry and medicinal chemistry; a small-scale cGMP clinical manufacturing facility and a large-scale cGMP commercial manufacturing plant in the Jinshan district of Shanghai; a large-scale non-GMP manufacturing plant in Changzhou; a preclinical toxicology facility in Suzhou; a laboratory for manufacturing research reagents in Suzhou; and a biologics manufacturing facility in Wuxi. It also offers services in biologics and medical device testing in three FDA-registered facilities in the United States. The Company has two segments: Laboratory services and Manufacturing services. Laboratory services are provided for pharmaceutical, biotechnology and medical device companies. China-based laboratory services for pharmaceutical and biotechnology companies include services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical services, genomics, research reagent production, and clinical services, as well as services for discovery and development of biologics. U.S.-based laboratory services include testing services for biologics, medical devices, and combination products. Manufacturing services include the development of manufacturing processes and the production of intermediates and active pharmaceutical ingredients, or APIs, for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologics. The Company offers testing and development services to ensure that a medical device is manufactured, packaged and sterilized in accordance with GMP guidelines. Its in vivo and in vitro toxicology testing includes biocompatibility or safe
WuXi PharmaTech (Cayman) (WuXi PharmaTech (Cayman)) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WX has been successfully added to your